A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune modulators into this study is based on preclinical and clinical data supportive of single-agent tolerability and potential clinical benefit, as well as non-clinical data suggesting safety, tolerability and clinical benefit of the agent(s) in combination with avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as follows:

• Combination A: avelumab plus utomilumab (4-1BB agonist mAb)
• Combination B: avelumab plus PF-04518600 (OX40 agonist mAb)
• Combination C: avelumab plus PD 0360324 (M-CSF mAb)
• Combination D: avelumab plus utomilumab plus PF-04518600
• Combination F: avelumab plus CMP-001 (TLR9 agonist) and avelumab plus CMP-001 plus utomilumab and avelumab plus CMP-001 and PF-04518600 Each combination will be studied individually in 2 study parts: 1) a Phase 1b Lead-in part to evaluate safety, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and RP2D (if applicable), of the combination, and 2) a Phase 2 part to evaluate efficacy and further evaluate safety of the selected dose from the Phase 1b portion in pre-specified patient populations.

• Drug: Avelumab
  Anti-PD-L1 antibody
  Other Name: MSB0010718C
• Drug: Utomilumab
  Anti-4-1BB antibody
  Other Name: PF-05082566
• Drug: PF-04518600
  OX40 Agonist
• Drug: PD 0360324
  Anti-M-CSF
• Drug: CMP-001
  TLR9 agonist

• Experimental: Cohort A1
  NSCLC patients treated with avelumab + utomilumab (Dose level 1)
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A2
  NSCLC patients treated with avelumab + utomilumab (Dose level 2)
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A3
  NSCLC patients treated with avelumab + utomilumab (Dose level 3)
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A4
  Melanoma patients treated with avelumab +utomilumab
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A5
  SCCHN patients treated with avelumab + utomilumab
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A6
  TNBC patients treated with avelumab + utomilumab
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A7
  SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A8
  NSCLC first-line Stage IV treated with avelumab +PF-05082566
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Combination B Dose Escalation
  PF-04518600 + avelumab in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: PF-04518600
• Experimental: Combination B Expansion Cohorts
  PF-04518600 + avelumab in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: PF-04518600
• Experimental: Combination C Dose escalation cohorts
  PD 0360324 + avelumab in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: PD 0360324
• Experimental: Combination C Dose expansion cohorts
  PD 0360324 + aveluamb in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: PD 0360324
• Experimental: Combination D Dose escalation cohorts
  PF-05082566 + PF-04518600 + avelumab in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
  • Drug: PF-04518600
• Experimental: Combination D Dose expansion cohorts
  PF-05082566 + PF-04518600 + avelumab in selected tumor types
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
  • Drug: PF-04518600
• Experimental: Cohort A9
  NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort A10
  NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
• Experimental: Cohort F1
  CMP-001 +avelumab in SCCHN
  Interventions:

  • Drug: Avelumab
  • Drug: CMP-001
• Experimental: Cohort F2
  CMP-001+avelumab+utomilumab in SCCHN
  Interventions:

  • Drug: Avelumab
  • Drug: Utomilumab
  • Drug: CMP-001
• Experimental: Cohort F3
  CMP-001 +avelumab+PF-04518600 in SCCHN
  Interventions:

  • Drug: Avelumab
  • Drug: PF-04518600
  • Drug: CMP-001

Inclusion Criteria:

• Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Combination F: Recurrent or metastatic SCCHN. One to three prior lines of systemic therapy for advanced stage or metastatic disease. Patients must have received anti PD-1/PD-L1 containing therapy (requires at least two doses of PD-1/PD-L1 agent).Disease progression no earlier than 6 weeks from initiation of the latest anticancer therapy. Evidence of radiologic progression is required. ? Patient must be a candidate for intralesional administration with at least one tumor lesion which can be injected safely.
• ECOG performance status 0 or 1
• Estimated life expectancy of at least 3 months
• Adequate bone marrow, renal, and liver function
• Resolved acute effects of prior therapy
• Negative serum pregnancy test at screening
• Male and female patients able to have children must agree to use at least 1 highly effective method of contraception throughout the study and for at least 90 days after last dose
• Signed and dated informed consent

Exclusion Criteria:

• Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14 days prior to study entry. Combination F:PD-1/PD-L1 agent within 14 days prior study entry.
• Current or prior use of immunosuppressive medication within 7 days prior to study entry
• Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
• Known prior or suspected hypersensitivity to investigational products
• Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
• Patients with known symptomatic brain metastases requiring steroids
• Previous high-dose chemotherapy requiring stem cell rescue
• Prior allogeneic stem cell transplant or organ graft
• Any of the following within 6 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
• Symptomatic pulmonary embolism within 6 months prior to study entry
• Known HIV or AIDS-related illness
• Active infection requiring systemic therapy
• Positive HBV or HCV test indicating acute or chronic infection
• Administration of a live vaccine within 4 weeks prior to study entry
• Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ?6) prostate cancer
• Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
• Persisting toxicity related to prior therapy >Grade 1
• Other severe acute or chronic medical condition
• Combo C :Existing periorbital edema.
• Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture (within 12 weeks prior study entry)